183 related articles for article (PubMed ID: 12953090)
1. Re: Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation carriers.
Foulkes WD
J Natl Cancer Inst; 2003 Sep; 95(17):1344; author reply 1344. PubMed ID: 12953090
[No Abstract] [Full Text] [Related]
2. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q
Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic surgery recommended for BRCA1 carriers.
Cancer Discov; 2014 May; 4(5):OF1. PubMed ID: 24795013
[No Abstract] [Full Text] [Related]
4. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
Agnantis NJ; Paraskevaidis E; Roukos D
Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
[No Abstract] [Full Text] [Related]
5. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
6. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
[No Abstract] [Full Text] [Related]
7. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic mastectomy: why and when?
von Smitten K
J Br Menopause Soc; 2003 Dec; 9(4):151-5. PubMed ID: 15107257
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in the clinical management of BRCA mutations carriers.
Savarese A; Cognetti F
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
Eur J Cancer; 2002 Nov; 38 Suppl 6():S15-7. PubMed ID: 12409058
[No Abstract] [Full Text] [Related]
12. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.
Roukos DH; Agnanti NJ; Paraskevaidis E; Kappas AM
Ann Surg Oncol; 2002 Dec; 9(10):941-3. PubMed ID: 12464584
[No Abstract] [Full Text] [Related]
13. Risk reduction works for BRCA mutation carriers--with heavy costs.
Vanchieri C
J Natl Cancer Inst; 2005 Jul; 97(14):1032-3. PubMed ID: 16030299
[No Abstract] [Full Text] [Related]
14. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
15. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Metcalfe KA; Birenbaum-Carmeli D; Lubinski J; Gronwald J; Lynch H; Moller P; Ghadirian P; Foulkes WD; Klijn J; Friedman E; Kim-Sing C; Ainsworth P; Rosen B; Domchek S; Wagner T; Tung N; Manoukian S; Couch F; Sun P; Narod SA;
Int J Cancer; 2008 May; 122(9):2017-22. PubMed ID: 18196574
[TBL] [Abstract][Full Text] [Related]
16. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
Friebel TM; Domchek SM; Neuhausen SL; Wagner T; Evans DG; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson G; Lynch HT; Tung N; Blum JL; Weitzel J; Rubinstein WS; Ganz PA; Couch F; Rebbeck TR
Clin Breast Cancer; 2007 Dec; 7(11):875-82. PubMed ID: 18269778
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 discovery led to patent debate, genetic screening.
Zielinski SL
J Natl Cancer Inst; 2004 Jul; 96(13):986. PubMed ID: 15240778
[No Abstract] [Full Text] [Related]
18. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
Hartmann LC; Lindor NM
N Engl J Med; 2016 Feb; 374(5):454-68. PubMed ID: 26840135
[No Abstract] [Full Text] [Related]
19. Online tool to guide decisions for BRCA1/2 mutation carriers.
Kurian AW; Munoz DF; Rust P; Schackmann EA; Smith M; Clarke L; Mills MA; Plevritis SK
J Clin Oncol; 2012 Feb; 30(5):497-506. PubMed ID: 22231042
[TBL] [Abstract][Full Text] [Related]
20. Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
Ann Intern Med; 2006 Mar; 144(6):I40. PubMed ID: 16549849
[No Abstract] [Full Text] [Related]
[Next] [New Search]